News headlines about Antares Pharma (NASDAQ:ATRS) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Antares Pharma earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 45.1109139813372 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have effected Accern’s scoring:

ATRS has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a research report on Friday, June 23rd. Chardan Capital initiated coverage on Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 target price on the stock. Vetr cut Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 target price on the stock. in a research report on Monday, June 26th. Finally, Piper Jaffray Companies set a $4.00 target price on Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Antares Pharma presently has a consensus rating of “Buy” and an average price target of $4.34.

Shares of Antares Pharma (ATRS) traded up 2.92% on Friday, reaching $3.88. 1,392,615 shares of the company were exchanged. The company’s market capitalization is $606.86 million. The stock has a 50 day moving average of $3.12 and a 200-day moving average of $2.97. Antares Pharma has a 52-week low of $1.41 and a 52-week high of $3.97.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The business had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. On average, analysts predict that Antares Pharma will post ($0.11) EPS for the current fiscal year.

In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 11.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/antares-pharma-atrs-given-daily-media-sentiment-rating-of-0-18/1613351.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.